[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346547-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346547-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","aldh1l2-orchestrates-redoxgrowth-coupling-in-renal-carcinoma-pan-cancer-evidence-and-mechanistic-validation-of-the-rosaktmtors6k-axis","ALDH1L2 orchestrates redox–growth coupling in renal carcinoma - pan-cancer evidence and mechanistic validation of the ROS–Akt/mTOR/S6K axis","","Aldehyde dehydrogenase family 1 member L2 (ALDH1L2) was systematically characterized for expression patterns, clinical relevance, and functional roles across cancers, with particular focus on urologic tumors. Using TCGA pan-cancer profiling, the study connected ALDH1L2 to outcomes, genomic and immune context, epigenetic associations, and stemness/heterogeneity indices. Immunohistochemistry assessed protein-level differences in BLCA, PRAD, and KIRC, while siRNA knockdown evaluated proliferation and motility via wound-healing, Transwell, and EdU assays. In KIRC, ALDH1L2 silencing elevated ROS and reduced Akt/mTOR/S6K phosphorylation, supporting a ROS–Akt/mTOR/S6K mechanism and divergent tumor roles.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/aldh1l2-orchestrates-redoxgrowth-coupling-in-renal-carcinoma-pan-cancer-evidence-and-mechanistic-validation-of-the-rosaktmtors6k-axis/346547/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/aldh1l2-orchestrates-redoxgrowth-coupling-in-renal-carcinoma-pan-cancer-evidence-and-mechanistic-validation-of-the-rosaktmtors6k-axis/346547.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main aim of the study on ALDH1L2?","Question",{"text":63,"@type":64},"To characterize ALDH1L2 expression patterns, clinical significance, and potential functions across cancers and validate its biological roles in urologic tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and experimental approaches were used to evaluate ALDH1L2?",{"text":68,"@type":64},"TCGA pan-cancer resource profiling was combined with immunohistochemistry in BLCA, PRAD, and KIRC, and siRNA-mediated ALDH1L2 knockdown in cell models using wound-healing, Transwell, and EdU assays.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanistic findings were reported for KIRC?",{"text":72,"@type":64},"ALDH1L2 silencing increased reactive oxygen species (ROS) levels and reduced Akt/mTOR/S6K phosphorylation, consistent with decreased EdU incorporation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346547,1790194414,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Original Research PUBLISHED 12 February 2026  \nDOI 10.3389/fimmu.2026.1768010  \nOPEN ACCESS  \nEDITED BY  \nInes Ambite,  \nLund University, Sweden  \nREVIEWED BY  \nLiang-min Fu,  \nThe First Afﬁliated Hospital of Sun Yat-sen University, China  \nGeorgia Persefoni Voulgaridou, Democritus University of Thrace, Greece  \n*CORRESPONDENCE  \nJinyou Wang  \n[jinyouwang@126.com](jinyouwang@126.com)[ ](jinyouwang@126.com)Yi Wang  \n [hbyiwang@126.com](hbyiwang@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 15 December 2025  \nREVISED 23 January 2026  \nACCEPTED 27 January 2026  \nPUBLISHED 12 February 2026  \nCITATION  \nJiang C, Liu S, Zhang L, Li S, Wang J and Wang Y (2026) ALDH1L2 orchestrates redox–growth coupling in renal carcinoma: pan-cancer evidence and mechanistic validation of the ROS–Akt/mTOR/S6K axis.  \nFront. Immunol. 17:1768010 .  \ndoi: 10.3389/fimmu.2026.1768010  \nCOPYRIGHT  \n© 2026 Jiang, Liu, Zhang, Li, Wang and Wang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nALDH1L2 orchestrates redox– growth coupling in renal carcinoma: pan-cancer evidence and mechanistic validation of the ROS–Akt/mTOR/S6K axis  \nChao Jiang †, Songsong Liu †, Liwen Zhang †, Shiji Li, Jinyou Wang* and Yi Wang*  \nDepartment of Urology, The Second Afﬁliated Hospital of Anhui Medical University, Hefei, China  \nBackground: Aldehyde dehydrogenase family 1 member L2 (ALDH1L2) has been relatively understudied in cancer. We aimed to systematically characterize its expression patterns, clinical signiﬁcance, and potential functions across cancersand to validate its biological roles in urologic tumors.  \nMethods: Leveraging The Cancer Genome Atlas pan-cancer resource, we proﬁled ALDH1L2 across tumor types with respect to expression patterns, clinical outcomes, genomic features, immune contexture, epigenetic associations, and indices of stemness and heterogeneity. Protein-level differences were examined by immunohistochemistry in bladder cancer (BLCA), prostate adenocarcinoma (PRAD), and kidney renal clear cell carcinoma (KIRC) tissues. To functionally interrogate ALDH1L2, we performed siRNA-mediated knockdown in relevant cell models and evaluated proliferation and motilityrelated phenotypes using wound-healing, Transwell, and EdU incorporation assays. In KIRC, Western blotting together with reactive oxygen species (ROS) detection was conducted to probe potential mechanistic links.  \nResults: ALDH1L2 was differentially expressed in multiple cancers and signiﬁcantly associated with overall and disease-speciﬁc survival in KIRC. IHC showed higher ALDH1L2 expression in KIRC tissues than in adjacent normal tissues, but lower expression in BLCA and PRAD. Functionally, ALDH1L2 knockdown suppressed proliferation and migration in KIRC cells, while promoting these processes in BLCA and PRAD cells. In KIRC, ALDH1L2 silencing increased ROS levels and reduced Akt/mTOR/S6K phosphorylation, consistent with decreased EdU incorporation.  \nConclusion: This study is the ﬁrst to systematically untangle the divergent roles of ALDH1L2 in KIRC, BLCA, and PRAD from a pan-cancer perspective combined with ex vivo experiments, suggesting that ALDH1L2 may serve as an important molecule inﬂuencing tumor progression and the immune microenvironment, thereby providing a new potential target for the diagnosis and treatment of related cancers.  \nKEYWORDS  \nALDH1L2, bladder cancer, kidney renal clear cell carcinoma, pan-cancer, prostate adenocarcinoma, RNA modiﬁcation, tumor immune microenvironment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIntroducti","cbCaimxyB7VUBgqs","https://ap.wps.com/l/cbCaimxyB7VUBgqs","pdf",17714862,16,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is the main aim of the study on ALDH1L2?\",\"answer\":\"To characterize ALDH1L2 expression patterns, clinical significance, and potential functions across cancers and validate its biological roles in urologic tumors.\"},{\"question\":\"Which datasets and experimental approaches were used to evaluate ALDH1L2?\",\"answer\":\"TCGA pan-cancer resource profiling was combined with immunohistochemistry in BLCA, PRAD, and KIRC, and siRNA-mediated ALDH1L2 knockdown in cell models using wound-healing, Transwell, and EdU assays.\"},{\"question\":\"What mechanistic findings were reported for KIRC?\",\"answer\":\"ALDH1L2 silencing increased reactive oxygen species (ROS) levels and reduced Akt/mTOR/S6K phosphorylation, consistent with decreased EdU incorporation.\"}]","ALDH1L2 orchestrates redox–growth coupling in renal carcinoma - pan-cancer evidence and mechanistic validation of the ROS–Akt/mTOR/S6K axis | PDF",1790061935,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9582f6b84b24e0d8ac2393ec0ef0a91.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90e7fa8a423991e33a5d828575bfbab5.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1c9ec49ecffa959673ee61e864fc13d.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78c2ce405a36e07f98a7ec368f889b24.webp",980,1385]